99.8% Raw material Formestane powder CAS 566-48-3 with C20H28O2

Place of Origin China
Brand Name XRD
Certification GMP
Model Number 566-48-3
Minimum Order Quantity negotiable
Price Inquiry for Negotiable
Packaging Details 1-2 kg / aluminum foil bag, 25kg/ drum, as required
Delivery Time 1-2days after payment received
Payment Terms T/T bank, Western Union, Bitcoin, Etc
Supply Ability 100KG/ Month

Contact me for free samples and coupons.

Whatsapp:0086 18588475571

Wechat: 0086 18588475571

Skype: sales10@aixton.com

If you have any concern, we provide 24-hour online help.

Product Details
CAS 566-48-3 Product Name Formestane
Type Anti-hair Loss Powder Appearance White Powder
Usage Anti-hair Loss Powder Alias NVP-QAW039
Assay 99% Key Words Formestane
High Light

pharmaceutical grade raw materials


intermediates in pharmaceuticals

Leave a Message
Product Description

99.8% Raw material Formestane powder CAS 566-48-3 with C20H28O2


Quick Details: 

1) Product Name: Supply Anti-hair loss powder high quality best price API Fevipiprant 872365-14-5
2) Purity: ≥99%
3) Appearance: White fine powder
4) Introduction:
Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2).[1][2][3
As of 2016, it is in Phase III[4] clinical trials for the treatment of asthma.[5]
Setipiprant (INN) (developmental code names ACT-129,968, KYTH-105) is a drug originally developed by Actelionwhich acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2).[1] It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients,[2][3] it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.

Anti-hair loss products


WAY 316606




RU 58841



CAS: 851723-84-7


CAS: 872365-14-5



CAS: 866460-33-5

WAY 316606
Description: Secreted Frizzled-related protein-1 (sFRP-1) inhibitor; increases Wnt signaling

Cortexolone 17 alpha-propionate (CB-03-01) is a new topical and peripherally selective androgen receptor antagonist.

RU 58841
RU58841 works by binding to the androgen receptor in the hair follicle. Therefore androgens don't have the chance to bind and start the chain reaction of androgenetic alopecia and begin the so called miniaturization process. It has been demonstrated to interrupt this hair loss message locally so that normal hair growth could continue.

OC000459 for the treatment of hair loss dwindled, perhaps due more to commercial potential and chemical stability reasons than efficacy as the later studies of OC000459 have focused on different chemical forms of the drug and combining it with various nanoparticles to enhance delivery. Recent years have seen the odd study pop up in relation to OC000459 and the treatment of acne and prostate cancer, which are conditions also driven by, however, the most recent study published in relation to OC000459 was back in 2008.

Setipiprant is an orally available, selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T helper [Th]-2 cells) antagonist. CRTH2 is a G protein-coupled receptor for prostaglandin (PGD2). PGD2 is produced by the mast cells and is a key mediator in various inflammatory diseases, including allergy and asthma. Binding of PGD2 to CRTH2, which are expressed on the surface of blood-borne cells, induces chemotaxis of Th2 cells, basophils, and eosinophils, and stimulates cytokine release from these cells. Thus, antagonism of CRTH2 receptors is considered to be a promising therapeutic target for various allergic diseases and asthma.

Fevipiprant, also known as NVP-QAW039 or QAW039, is an oral active and potent CRTh2 receptor antagonist and potentially useful for asthma treatment. [(3)H]-QAW039 displayed high affinity for the human CRTh2 receptor (1.14 ± 0.44 nM) expressed in Chinese hamster ovary cells, the binding being reversible and competitive with the native agonist prostaglandin D2(PGD2). QAW039 was also a potent inhibitor of PGD2-induced cytokine release in human Th2 cells. Fevipiprant reduces eosinophilic airway inflammation and is well tolerated in patients with persistent moderate-to-severe asthma and raised sputum eosinophil counts despite inhaled corticosteroid treatment. Fevipiprant demonstrates a favorable safety profile.



99.8% Raw material Formestane powder CAS 566-48-3 with C20H28O2 0


99.8% Raw material Formestane powder CAS 566-48-3 with C20H28O2